[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 2007

Investigating the Burden of Wet Macular Degeneration

Arch Ophthalmol. 2007;125(9):1266-1268. doi:10.1001/archopht.125.9.1266

Wet (also called neovascular) macular degeneration is a chronic, progressive eye condition that mainly affects people aged 60 years and older. It is estimated that the disease affects around 2 million people across Europe1 and 1.25 million in the United States.2 Wet macular degeneration is the leading cause of blindness in people older than 65 years in the developed world. A number of treatments are available, but they are not suitable for all cases of wet macular degeneration. Where treatment is appropriate, it does not cure the condition but rather halts or limits its progress, though newer treatments may bring about improvements for some patients. Macular degeneration is usually bilateral and its impact on patients can be devastating.3

First Page Preview View Large
First page PDF preview
First page PDF preview